Boston gets two Big Medtech execs on board
This article was originally published in Clinica
Boston Scientific has brought in two new board members, both well-known veterans of the medtech industry. Charles Dockendorff, former executive vice-president and chief financial officer of Covidien, and Stephen MacMillian, current president and CEO of Hologic, will join Boston’s board of directors, effective 1 April. They will take the seats of Uwe Reinhardt and Bruce Byrnes, who will not stand for re-election at Boston’s annual stockholder meeting in May.